Table 5

Correlations of clinical features with SSc associated autoantibodies

ACA

(310)

ATA

(260)

Anti-PM-Scl

(42)

Anti-U1-RNP

(41)

Anti-RNA -P

(33)

Anti-Fibrillarin

(12)

Anti-Ku

(10)

Anti-Ro52

(187)

Anti-Ro60

(59)

Anti-La

(16)

AMA

(41)

Anti-p25/23

(28)

ANA-negative

(50)

no SSc associated ab's

(161)


male sex

148 (17.1%)

17

0.19 (0.11 to 0.32)

P < 0.0001

64

2.02 (1.4 to 2.91)

p = 0.0002

6

9

8

4

2

23

0.62 (0.38 to 0.997

p = 0.049

12

2

1

1

10

41

1.90 (1.261 to 2.863)

p = 0,0035

age at disease onset < 50 y

399/781 (51.1%)

115

0.57 (0.43 to 0.77)

p = 0.0003

135

1.39 (1.02 to 1.88)

p = 0.0431

22

29

2.92 (1.40 to 6.07)

p = 0.0029

13

8

4

77

31

10

20

8

18

73

Rodnan skin score > 10

294/750 (39.2%)

58

0.27 (0.19 to 0.38)

P < 0.0001

132

3.10 (2.24 to 4.27)

P < 0.0001

14

9

18

3.24 (1.44 to 7.31)

p = 0.0042

7

1

58

23

6

10

11

14

56

Raynaud's phenomenon

819 (94.9%)

301

2.26 (1.07 to 4.77)

p = 0.0349

252

37

41

32

12

10

184

3.96 (1.2 to 12.94

p = 0.0133

58

16

41

28

43

0.29 (0.12 to 0.70)

p = 0.0104

140

0.23 (0.12 to 0.42)

P < 0.0001

Digital ulcers

216/840 (25.7%)

55

0.50 (0.36 to 0.71)

P < 0.0001

106

3.18 (2.30 to 4.41)

P < 0.0001

9

11

7

4

1

48

19

6

13

6

4

0.26 (0.09 to 0.76)

p = 0.0076

28

0.60 (0.39 to 0.94)

p = 0.024

Pulmonary hypertension

126 (14.6%)

57

1.58 (1.08 to 2.32)

p = 0.0208

36

2

9

4

1

0

31

14

2

2

7

2

0.23 (0.06 to 0.97)

p = 0.0232

17

Pulmonary fibrosis

287 (33.3%)

39

0.18 (0.12 to 0.26)

P < 0.0001

151

4.76 (3.48 to 6.50)

P < 0.0001

16

11

7

2

6

69

30

2.20 (1.29 to 3.75

p = 0.0040

9

6

0.33 (0.14 to 0.79)

p = 0.01

4

0.33 (0.11 to 0.95)

p = 0.0393

11

55

Lung restrictive defect

218/833 (26.2%)

41

0.31 (0.21 to 0.45)

P < 0.0001

104

2.96 (2.14 to 4.09)

P < 0.0001

9

7

8

3

4

45

19

4

8

4

10

34

Esophageal involvement

535 (62.0%)

198

175

1.39 (1.02 to 1.89)

p = 0.039

14

0.29 (0.152 to 0.56)

p = 0.0001

29

20

7

6

120

39

13

24

21

27

87

0.67 (0.47 to 0.94)

p = 0.0243

Proteinuria

90/830 (10.8%)

23

0.56 (0.34 to 0.92)

p = 0.0207

34

4

4

4

1

1

15

9

2

3

1

5

19

Cardiac involvement

114 (13.2%)

27

0.51 (0.32 to 0.81)

p = 0.0033

45

1.62 (1.08 to 2.44)

p = 0.0216

5

7

5

1

2

20

9

1

4

1

5

22

Musculoskeletal involvement

421/852 (49.4%)

131

0.64 (0.48 to 0.85)

p = 0.0022

130

20

28

2.49 (1.25 to 4.96)

p = 0.009

17

10

5.22 (1.14 to 23.97)

p = 0.0202

6

80

0.71 (0.51 to 0.99)

p = 0.0468

32

12

3.13 (1.002 to 9.79)

p = 0.0447

17

9

25

79

Synovitis

157/837 (18.8%)

35

0.43 (0.29 to 0.65)

P < 0.0001

62

1.71 (1.19 to 2.45)

p = 0.0049

8

13

2.27 (1.14 to 4.53)

p = 0.0326

8

2

2

32

15

5

2

0.21 (0.05 to 0.89)

p = 0.0216

2

10

29

Joint contractures

253/840 (30.1%)

54

0.36 (0.25 to 0.50)

P < 0.0001

107

2.26 (1.65 to 3.08)

P < 0.0001

9

9

10

6

2

49

23

6

9

9

20

1.93 (1.05 to 3.54)

p = 0.0436

56

Tendon friction rubs

88/840 (10.5%)

14

0.30 (0.16 to 0.53)

P < 0.0001

32

2

5

6

3

1

21

5

2

2

0

6

25

1.95 (1.18 to 3.22)

p = 0.0122

CK elevation

74/835 (8.9%)

14

0.37 (0.21 to 0.68)

p = 0.0009

20

19

3.56 (1.67 to 7.57)

p = 0.0023

5

6

2.60 (1.03 to 6.55)

p = 0.0485

0

3

5.32 (1.30 to 21.72)

p = 0.038

21

8

2

1

0

6

16

Sicca syndrome

366/858 (42.7%)

150

1.44 (1.19 to 6.61)

p = 0.0119

98

14

18

12

5

4

96

1.57 (1.13 to 2.17)

p = 0.0075

33

1.85 (1.08 to 3.17)

p = 0.0275

12

4.14 (1.32 to 12.93)

p = 0.0102

19

20

3.50 (1.52 to 8.03)

p = 0.0029

23

66

Mouth involvement

223/829 (26.9%)

64

0.61 (0.44 to 0.85)

p = 0.0034

93

2.1 (1.53 to 2.93)

P < 0.0001

10

7

10

3

4

49

18

6

11

6

12

34

ESR > 25 mm/h

199/741 (26.9%)

58

0.70 (0.49 to 0.99)

p = 0.046

75

1.55 (1.10 to 2.19)

p = 0.015

4

0.33 (0.11 to 0.94)

p = 0.0325

14

5

0

0

60

1.76 (1.21 to 2.54)

p = 0.0039

28

3.39 (1.92 to 5.97)

P < 0.0001

9

3.62 (1.33 to 9.86)

p = 0.0447

10

5

15

42


ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; CK, creatine kinase; ESR, erythrocyte sedimentation rate; RNAP = RNA polymerase; RNP = ribonucleoprotein; SSc, systemic sclerosis. Dichotomous variables are expressed as raw numbers, OR (95% CI) and P values.

Mierau et al. Arthritis Research & Therapy 2011 13:R172   doi:10.1186/ar3495

Open Data